GENTAMICIN SULFATE

Manufacturer
STAT RX USA LLC
Effective date
2011-03-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:11:32

Label at a glance#

ProductGENTAMICIN SULFATE
Active ingredientGENTAMICIN SULFATE
Label structure10 sections

Indications and uses

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Ge...

Dosage and administration

A small amount of gentamicin sulfate cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. I...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For Dermatologic Use Only

Not For Ophthalmic Use

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Gentamicin Sulfate Cream is a wide spectrum antibiotic preparation for topical administration. Each gram contains Gentamicin Sulfate USP equivalent to 1 mg gentamicin base in a cream base containing stearic acid, propylene glycol monostearate, isopropyl myristate, polysorbate 40, propylene glycol, sorbitol solution and purified water with methylparaben and butylparaben as preservatives.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Cream usually clears the lesions promptly. In secondary skin infections, Gentamicin Sulfate Cream aids in the treatment of the underlying dermatoses by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Kiebsiella pneumoniae.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin sulfate cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin sulfate cream has been used successfully in infants over one year of age, as well as in adults and children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In patients with dermatoses treated with gentamicin sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with gentamicin sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of gentamicin sulfate followed by exposure to ultraviolet radiation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of gentamicin sulfate cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gentamicin Sulfate Cream USP, 0.1% is supplied in 15 gram tubes NDC 0168-0071-15.

Store at controlled room temperature 15°-30°C (59°-86°F).

E. FOUGERA and CO. A division of Nycomed US Inc.
MELVILLE, NEW YORK 11747

I27115D
#294
R2/08

GENTAMICIN SULFATE CREAM USP, 0.1%

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Label ImageLabel Image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197735gentamicin sulfate 0.1 % Topical CreamPSN1
197735gentamicin 1 MG/ML Topical CreamSCD1
197735gentamicin (as gentamicin sulfate) 0.1 % Topical CreamSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
GENTAMICIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
3b7b3a7a-635f-32a3-0c6c-7ad028e3de91Product name220250107
43025f0d-698c-68da-cec9-ea4261a7ef7aProduct name220250107
d3946667-8212-d1f2-67e1-5643a329bb56Product name220200403
4ce5dce5-e8a7-e4f6-0059-b527e4307477Product name220190501
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
16590-107-152019-10-29C16284748780-1960f7f55-c485-8e05-e053-dbdaa90a074ae2eed774-9a41-4a03-b8c0-e785fabf3228

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
16590-107-15GENTAMICIN SULFATE15 g in 1 TUBECREAM151

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
16590-107GENTAMICIN SULFATE CREAM [STAT RX USA LLC]11 package rows20110321_e2eed774-9a41-4a03-b8c0-e785fabf3228.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
16590-107-15GM - Gram16590-1075beae385-a12b-4af5-aa55-e494ba845f8f12015-02-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
GENTAMICIN SULFATEACTIVE INGREDIENT8X7386QRLV1
GENTAMICINACTIVE MOIETYT6Z9V48IKG1
BUTYLPARABENINACTIVE INGREDIENT3QPI1U3FV81
ISOPROPYL MYRISTATEINACTIVE INGREDIENT0RE8K4LNJS1
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T1
POLYSORBATE 40INACTIVE INGREDIENTSTI11B5A2X1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
PROPYLENE GLYCOL MONOSTEARATEINACTIVE INGREDIENTF76354LMGR1
SORBITOLINACTIVE INGREDIENT506T60A25R1
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65AP1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
16590-10716590-107-15
0168-0071

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 5 · 276 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SORBITOLSORBITOL506T60A25RTABLET, CHEWABLE / ORAL3555 mgExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPOWDER, FOR SOLUTION / ORAL126 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TPASTE, DENTIFRICE / DENTAL0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCAPSULE / ORAL7 mgExact identifier — unii candidate
79 equally ranked IID candidates
POLYSORBATE 40POLYSORBATE 40STI11B5A2XLOTION / TOPICAL40 mgExact identifier — unii candidate
7 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / SOFT TISSUE0.15 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APCAPSULE / ORAL90 mgExact identifier — unii candidate
26 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RGUM, CHEWING / ORAL6168 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAMUSCULAR7459 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / DENTALNAExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RLOTION / TOPICAL10.7 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3DROPS / ORAL200 mg/1mlExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, METERED / RECTALNAExact identifier — unii candidate
81 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSFILM, EXTENDED RELEASE / TRANSDERMAL20.4 mgExact identifier — unii candidate
18 equally ranked IID candidates
PROPYLENE GLYCOL MONOSTEARATEPROPYLENE GLYCOL MONOPALMITOSTEARATEF76354LMGRCREAM / TOPICAL9.3 %w/wExact identifier — unii candidate
6 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8LOTION / TOPICAL4 mgExact identifier — unii candidate
15 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
79 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8SYRUP / ORAL28.4 mg/1mlExact identifier — unii candidate
15 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RINJECTION / INTRA-ARTICULAR45 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / INTRAMUSCULAR45 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / ORAL27120 mgExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSUSPENSION / RECTAL46.18 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / TOPICAL4886 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / RECTAL1214 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / TOPICAL5.28 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION, CONCENTRATE / ORAL1 mg/1mlExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, COATED / ORAL16 mgExact identifier — unii candidate
81 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RINJECTION, SOLUTION / SUBCUTANEOUS4.7 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SHAMPOO / TOPICAL8 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APSHAMPOO / TOPICAL9.7 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3EMULSION / TOPICAL8 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGRANULE, FOR SUSPENSION / ORAL80 mgExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RCREAM, AUGMENTED / TOPICAL15 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii candidate
81 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSOIL / TOPICAL213 mgExact identifier — unii candidate
18 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8SOLUTION / RECTAL0.01 %w/vExact identifier — unii candidate
15 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSUSPENSION / ORAL45000 mgExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8SOLUTION / ORAL6 mgExact identifier — unii candidate
15 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET, DELAYED RELEASE / ORAL80 mgExact identifier — unii candidate
26 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / EPIDURAL30 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLENE GLYCOL MONOSTEARATEPROPYLENE GLYCOL MONOPALMITOSTEARATEF76354LMGRSUPPOSITORY / VAGINAL135 mgExact identifier — unii candidate
6 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, EXTENDED RELEASE / TRANSDERMAL58.13 mgExact identifier — unii candidate
81 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRADERMAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSHAMPOO, SUSPENSION / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TFILM, SOLUBLE / BUCCAL3 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / INTRAMUSCULAR95 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RTABLET, ORALLY DISINTEGRATING / ORAL7 mgExact identifier — unii candidate
44 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
81 equally ranked IID candidates
POLYSORBATE 40POLYSORBATE 40STI11B5A2XGEL / TOPICAL28 mgExact identifier — unii candidate
7 equally ranked IID candidates
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8TABLET / ORALNAExact identifier — unii candidate
15 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RELIXIR / ORAL833.3 mgExact identifier — unii candidate
44 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSPRAY / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION/ DROPS / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSAEROSOL, FOAM / TOPICAL144 mgExact identifier — unii candidate
18 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062531-001GENTAMICIN SULFATEGENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0584e616aacf4f…
2026-08-18 06:07:402026-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0531067a03dcf5…
2025-08-23 18:47 UTC2025-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-056a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-052680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-051e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-058072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-054b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-0587673890dc5c…
2021-03-12 10:30 UTC2021-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-055aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-058869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053f01610625f2…
2019-09-15 20:21 UTC2019-09A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05b00525d2431f…
2019-07-19 19:46 UTC2019-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-056a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-051c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-059b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053f0d92c62455…
2023-05-13 08:27 UTC2023-05A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05053a50430f4f…
2023-01-26 05:58 UTC2023-01A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-053a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062531-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICAL1984-07-05f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
75426d61-72dc-41be-abda-689807061bece2eed774-9a41-4a03-b8c0-e785fabf32282011-03-17Adverse reactionsExact identifier
spl id: 75426d61-72dc-41be-abda-689807061bec
spl set id: e2eed774-9a41-4a03-b8c0-e785fabf3228

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.